Serum adiponectin and resistin levels in major depressive disorder

Authors: Lehto, S. M.; Huotari, A.; Niskanen, L.1; Tolmunen, T.2; Koivumaa-Honkanen, H.3; Honkalampi, K.4; Ruotsalainen, H.5; Herzig, K.-H.; Viinamäki, H.2; Hintikka, J.2

Source: Acta Psychiatrica Scandinavica, Volume 121, Number 3, March 2010 , pp. 209-215(7)

Publisher: Wiley-Blackwell

Buy & download fulltext article:


Price: $48.00 plus tax (Refund Policy)


Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig K-H, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Objective: 

To examine the role of the adipose-tissue-derived low-grade inflammation markers adiponectin and resistin in major depressive disorder (MDD) in a population-based sample. Method: 

Serum levels of adiponectin and resistin were measured from 70 DSM-IV MDD subjects and 70 healthy controls. Depression severity was assessed with the 29-item Hamilton Depression Rating Scale. Results: 

The MDD group had lowered serum adiponectin levels. Regression modelling with adjustments for age, gender, overweight, several socioeconomic and lifestyle factors, coronary heart disease and metabolic syndrome showed that each 5.0 μg/ml decrease in serum adiponectin increased the likelihood of MDD by approximately 20% (P = 0.01). The resistin levels correlated with atypical (P = 0.02), but not with typical depressive symptoms (P = 0.12). Conclusion: 

Our findings suggest that the lowered adiponectin levels in MDD are depression-specific and not explained by conventional low adiponectin-related factors such as such as coronary heart disease and metabolic disorders.

Keywords: adiponectin; coronary heart disease; major depressive disorder; metabolic syndrome, resistin

Document Type: Research Article


Affiliations: 1: Department of Medicine, Kuopio University Hospital and University of Kuopio, Kuopio, Finland 2: Department of Psychiatry, Kuopio University Hospital and University of Kuopio, Kuopio, Finland 3: Department of Psychiatry, University of Oulu & Lapland Hospital District, Rovaniemi, Finland 4: Kuopio Psychiatric Center, Kuopio, Finland 5: Institute of Biomedicine, Division of Physiology and Biocenter Oulu, University of Oulu, Finland

Publication date: March 1, 2010



Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page